The role of cytokines in both the normal and malignant ovary

Endocrine-Related Cancer

Volumn 6, Issue 1, 1999, Pages 93-107

  Nash, M A ^a   Ferrandina, G ^b   Gordinier, M ^a   Loercher, A ^a   Freedman, R S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

CANCER GROWTH; CANCER IMMUNOLOGY; CONTROLLED STUDY; FEMALE; GROWTH REGULATION; HUMAN; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGEN PRESENTATION; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; NEUTROPENIA; OVARIAN NEOPLASMS; OVARY; OVULATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032893042     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060093     Document Type: Review

References (122)

1. Arici A, MacDonald PC & Casey ML 1996 Modulation of the levels of interleukin-8 messenger ribonucleic acid and interleukin-8 protein synthesis in human endometrial stromal cells by transforming growth factor-beta 1. Journal of Clinical Endocrinology and Metabolism 81 3004-3009.
2. Arici A, Oral E, Bukulmez O, Buradagunta S, Bahtiyar O & Jones EE 1997 Monocyte chemotactic protein-1 expression in human preovulatory follicles and ovarian cells. Journal of Reproductive Immunology 32 201-219.
3. Aso H, Tamura K, Yoshie O, Nakamura T, Kikuchi S & Ishida N 1992 Impaired NK response of cancer patients to IFN-alpha but not to IL-2: correlation with serum immunosuppressive acidic protein (IAP) and role of suppressor macrophage. Microbiology and Immunology 36 1087-1097.
4. Asschert JG, Vellenga E, Hollema H, van der Zee AG & de Vries ED 1997 Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumor necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas. European Journal of Cancer 33 2246-2251.
5. Auvinen P, Lipponen P, Johansson R & Syrjänen K 1995 Prognostic significance of TGF-betal and TGF-beta2 expressions in female breast cancer. Anticancer Research 15 2627-2631.
6. Baiocchi G, Scambia G, Benedetti P, Menichella G, Testa U, Pierelli L, Martucci R, Foddai ML, Bizzi B, Mancuso S & Peschle C 1993 Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery. Cancer Research 53 1297-1303.
7. Balkwill FR 1992 Tumor necrosis factor and cancer. Progress in Growth Factor Research 4 121-137.
8. Barrack ER 1997 TGFbeta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31 61-70.
9. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM & Martinez-Maza O 1991 Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. American Journal of Obstetrics and Gynecology 164 1038-1042.
10. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Phillip T & Favrot M 1992 Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Research 52 3317-3322.
11. 1. Blood 83 3462-3467.
12. Branisteanu I, Pijenborg R, Spiessens C, Van der Auwera I, Keith JCJ & Van Assche FA 1997 Detection of immunoreactive interleukin-11 in human follicular fluid: correlations with ovarian steroid, insulin-like growth factor-I levels, and follicular maturity. Fertility and Sterility 67 1054-1058.
13. Burke F, Relf M, Negus R & Balkwill F 1996 A cytokine profile of normal and malignant ovary. Cytokine 8 578-585.
14. Castelli M, Battaglia F, Scambia G, Panici PB, Ferrandina G, Mileo AM, Mancuso S & Ferrini U 1991 Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer. Oncology 48 13-17.
15. Chambers SK, Kacinski BM, Ivins CM & Carcangiu ML 1997 Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor - a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clinical Cancer Research 3 999-1007.
16. Chegini N & Flanders KC 1992 Presence of transforming growth factor-β and their selective cellular localization in human ovarian tissue of various reproductive stages. Endocrinology 130 1303-1307.
17. null mice is prognostic for a high risk of malignant conversion. Cancer Research 54 5831-5836.
18. Czarniecki CW, Chiu HH, Wong GHW, McCabe SM & Palladino MA 1988 Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells. Journal of Immunology 140 4217-4223.
19. D'Hondt V, Humblet Y, Guuillaume T, Baatout S, Chetelain C, Berliere M, Bongueville J, Feyens AM, de Greve J, Van Oosterom A, Von Graffenried B, Donnez J & Symann M 1995 Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. Blood 85 2347-2353.
20. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A & Catalano G 1998 Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncology Reports 5 649-652.
21. De Winter JP, Roelen BAJ, Ten Dijke P, Van der Burg B & Van den Eijnden-van Raaij A 1997 DPC4 (SMAD4) mediates transforming growth factor-betal (TGF-beta1)-induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14 1891-1899.
22. Donnet-Hughes A, Schiffrin EJ & Huggett AC 1995 Expression of MHC antigens by intestinal epithelial cells. Effect of transforming growth factor-beta 2 (TGF-β2). Clinical and Experimental Immunology 99 240-244.
23. Erroi A, Sironi M, Chiaffarino F, Chen ZG, Mengozzi M & Mantovani A 1989 IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. International Journal of Cancer 44 795-801.
24. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I & Sobol RE 1996 Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proceedings of the National Academy of Sciences of the USA 93 2909-2914.
25. Farber L, Haus U, Fuchsel G, Theml H, Chatsiproios D, Schmid H, Burger KJ & Drechsler S 1997 Treatment of prolonged chemotherapy induced severe thrombocytopenia with recombinant human interleukin-3 - a report on four cases. Anti-Cancer Drugs 8 288-292.
26. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore K W & O'Garra A 1991 IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. Journal of Immunology 146 3444-3451.
27. Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M & Platsoucas CD 1998 Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cellular and Molecular Therapy 4 121-140.
28. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH & Rubin SC 1993 High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. British Journal of Haematology 83 433-441.
29. Gordinier M, Zhang HZ, Kidd L, Patenia R, Levy L, Katz RL, Nash MA, Edwards CL, Platsoucas CD & Freedman RS 1998 Quantitative analysis of transforming growth factor-b (TGF-b) and HLA class I and II in epithelial ovarian cancer. Proceedings of the Annual Meeting of the American Association for Cancer Research 39 A1033.
30. Gotlieb WH, Abrams JW, Watson JM, Velu TJ, Berek JS & Martinez-Maza O 1992 Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4 385-390.
31. Henriksen R, Gobi A, Wilander E, Berg K, Miyazono K & Funa K 1995 Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Laboratory Investigation 73 213-220.
32. Herrmann S & Abdi K 1996 Both IL-2 and IL-4 synergize with IL-12 to induce a CTL response, a response completely blocked by TGF-beta. Annals of the New York Academy of Sciences 795 168-180.
33. Hirte H & Clark DA 1991 Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-β as a suppressive factor. Cancer Immunology and Immunotherapy 32 296-302.
34. Huleihel M, Maymon E, Piura B, Prinsloo I, Benharroch D, Yanai-Inbar I & Glezerman M 1997 Distinct patterns of expression of interleukin-1 alpha and beta by normal and cancerous human ovarian tissues. European Cytokine Network 8 179-187.
35. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC & Berchuck A 1994 Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74 93-99.
36. Jasper MJ, Brannstrom M, Olofsson JI, Petrucco OM, Mason H, Robertson SA & Norman RJ 1996 Granulocyte-macrophage colony-stimulating factor: presence in human follicular fluid, protein secretion and mRNA expression by ovarian cells. Molecular Human Reproduction 2 555-562.
37. Johnson MT, Watson JM, Berek JS & Martinez-Maza O 1992 Interleukin 6 induces resistance of ovarian tumors by natural killer cell-mediated cytotoxcity. Proceedings of the Society for Gynecologic Investigation (Abstract).
38. Kacinski BM, Stanley ER, Carter D, Chambers JT, Chambers SK, Kohorn EI & Schwartz PE 1989 Circulating levels of CSF-1 (M-CSF), a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. International Journal of Radiation Oncology, Biology, Physics 17 159-164.
39. Kaipia A & Hsueh AJ 1997 Regulation of ovarian follicle atresia. Annual Review of Physiology 59 349-363.
40. Kaufmann M, Schmid H, Raeth U, Grischke EM, Kembeni J, Schlick E & Bastert G 1990 Therapy of ascites with tumor necrosis factor in ovarian cancer. Geburtshilfe und Frauenheilkunde 50 678-682.
41. Kawabata M, Imamura T, Miyazono K, Engel ME & Moses HL 1995 Interaction of the transforming growth factor-β type I receptor with farnesyl-protein transferase-α. Journal of Biological Chemistry 270 29628-29631.
42. Klingemann HG 1989 Clinical applications of recombinant human colony-stimulating factors. CMAJ 140 137-142.
43. Ko TC, Sheng HM, Reisman D, Thompson EA & Beauchamp RD 1995 Transforming growth factor-β1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene 10 177-184.
44. Lanzavecchia A 1993 Identifying strategies for immune intervention. Science 260 937-944.
45. Lee LF, Schuerer-Maly CC, Lofquist AK, van Haaften-Day C, Ting JP, White CM, Martin BK & Haskill JS 1996 Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Research 56 1303-1308.
46. Lidor YJ, Xu FJ, Martinez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS & Bast RCJ 1993 Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Experimental Cell Research 207 332-339.
47. Liu F, Pouponnot C & Massagu J 1997 Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes and Development 11 3157-3167.
48. Loercher AE, Nash MA, Edwards CL, Platsoucas CD & Freedman RS 1998 IL-10 producing monocytes in malignant ascites from ovarian cancer patients. Proceedings of the Annual Meeting of the American Association for Cancer Research 39 A1032.
49. Lynch MA, Nakashima R, Song H, DeGroff VL, Wang D, Enomoto T & Weghorts CM 1998 Mutational anlaysis of the transforming growth factor B receptor type II gene in human ovarian carcinoma. Cancer Research 58 4227-4232.
50. Machelon V, Nome F & Salesse R 1994 Comparative IL-6 effects on FSH and hCG-induced functions in porcine granulosa cell cultures. Cellular and Molecular Biology 40 373-380.
51. MacKay SL, Yaswen LR, Tarnuzzer RW, Moldawer LL, Bland KI, Copeland EM III & Schultz GS 1995 Colon cancer cells that are not growth inhibited by TGF-β lack functional type I and type II TGF-β receptors. Annals of Surgery 221 767-777.
52. Maeda H & Shiraishi A 1996 TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. Journal of Immunology 156 73-78.
53. Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S & Shirashi A 1995 TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. Journal of Immunology 155 4926-4932.
54. Marth C, Lang T, Koza A, Mayer I & Daxenbichler G 1990 Transforming growth factor-beta and ovarian carcinoma cells: regulation of proliferation and surface antigen expression. Cancer Letters 51 221-225.
55. Massagúe J, Hata A & Liu F 1997 TGF-beta signalling through the Smad pathway. Trends in Cell Biology 7 187-192.
56. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang Q-J, Masucci MG & Kiessling R 1994 Interleukin 10 pretreatment protects target cells from tumor- and allospecific cytotoxic T cells and downregulates HLA class I expression. Journal of Experimental Medicine 180 2371-2376.
57. Melichar B, Savary C, Kudelka AA, Verschraegen C, Kavanagh JJ, Edwards CL, Platsoucas CD & Freedman RL 1998 Lineage negative HLA-DR positive cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clinical Cancer Research 4 799-809.
58. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD & Freeman SM 1997 Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Human Pathology 28 321-331.
59. Moradi MM, Carson LF, Weinberg JB, Haney AF, Twiggs LB & Ramakrishnan S 1993 Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 72 2433-2440.
60. Morstyn G, Lieschke GJ, Sheridan W, Layton J, Cebon J & Fox RM 1989 Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. Seminars in Hematology 26 9-13.
61. Mosmann TR & Coffman RL 1989 TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology 7 145-173.
62. Mulheron GW, Danielpour D & Schomberg DW 1991 Rat thecal/interstitial cells express transforming growth factor-β type 1 and 2, but only type 2 is regulated by gonadrotropin in vitro. Endocrinology 129 3368-3374.
63. Nash MA, Lenzi R, Edwards CL, Kavanagh JJ, Kudelka AP, Verschraegen CF, Platsoucas CD & Freedman RS 1998 Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumor specimens, peritoneal exudate cells containing tumor, TIL-derived T-cell lines and established tumor cell lines. Clinical and Experimental Immunology 112 172-180.
64. Obata NH, Tamakoshi K, Shibata K, Kikkawa F & Tomoda Y 1997 Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human carcinoma. Anticancer Research 17 337-342.
65. Offner FA, Obrist P, Stadimann S, Feichtinger H, Klingler P, Herold M, Zwierzina H, Hittmair A, Mikuz G, Abendstein B et al. 1995 IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 7 542-547.
66. Ohtsuki F, Yamamoto M, Nakagawa T, Tanizawa T & Wada H 1997 Granulocyte-macrophage colony-stimulating factor abrogates transforming growth factor-beta1-mediated cell cycle arrest by up-regulating cyclin D2 Cdk6. British Journal of Haematology 98 520-527.
67. Pardoll DM 1998 Cancer vaccines. Nature Medicine 4 525-531.
68. Park K, Kim S-J, Bang Y-J, Park J-G, Kim NK, Roberts AB & Sporn MB 1994 Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proceedings of the National Academy of Sciences of the USA 91 8772-8776.
69. Parsons R, Myeroff LL, Liu B, Willson JKV, Markowitz SD, Kinzler KW & Vogelstein B 1995 Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Research 55 5548-5550.
70. Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B & Kiessling R 1992 Selective expression of interleukin 10, interferon γ, and granulocyte-macrophage colony stimulating factor in ovarian cancer biopsies. Proceedings of the National Academy of Sciences of the USA 89 7708-7712.
71. Price FV, Chambers SK, Chambers JT, Carcangiu ML, Schwartz PE, Kohorn EI, Stanley ER & Kacinski BM 1993 Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. American Journal of Obstetrics and Gynecology 168 520-527.
72. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S & Brandely M 1996 Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. Journal of Clinical Oncology 14 343-350.
73. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R & Whiteside TL 1996 Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. International Journal of Cancer 68 276-284.
74. Ravitz MJ, Yan S, Herr KD & Wenner CD 1995 Transforming growth factor β-induced activation of cyclin E-cdk2 kinase and down-regulation of p27Kip1 in C3H 10T mouse fibroblasts. Cancer Research 55 1413-1416.
75. Reed JA, McNutt NS, Prieto VG & Albino A P 1994 Expression of transforming growth factor-β2 in malignant melanoma correlates with the depth of tumor invasion. American Journal of Pathology 145 97-104.
76. Riggins GJ, Kinzler KW, Vogelstein B & Thiagalingam S 1997 Frequency of Smad gene mutations in human cancers. Cancer Research 57 2578-2580.
77. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF & Sporn MB 1985 Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proceedings of the National Academy of Sciences of the USA 82 119-123.
78. Roberts AB, Sporn MB, Assoian RK, Smith JM, Rouche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Dehrl JH & Fauci AS 1986 Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proceedings of the National Academy of Sciences of the USA 83 4167-4171.
79. Rosenberg RA 1997 Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunology Today 18 175-182.
80. Runesson E, Bostrom EK, Janson PO & Brannstrom M 1996 The human preovulatory follicle is a source of the chemotactic cytokine interleukin-8. Molecular Human Reproduction 2 245-250.
81. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL & Doetschman T 1997 TGFbeta2 knockout mice have multiple developmental defects that are nonoverlapping with other TGFbeta knockout phenotypes. Development 124 2659-2670.
82. Santin A, Hiserodt JC, Disaia PJ, Pecorelli S & Granger GA 1996 Production of transforming growth factor-beta in fresh and established human ovarian cancer. Gynecologic Oncology 61 403-408.
83. Sarandakou A, Phocas I, Sikiotis K, Rizos D, Botsis D, Kalambokis K, Trakakis E & Chryssikopoulos A 1997 Cytokines in gynecological cancer. Anticancer Research 17 3835-3839.
84. Satterwhite DJ & Moses HL 1994 Mechanisms of transforming growth factor-beta1-induced cell cycle arrest. Invasion Metastasis 14 309-318.
85. Sawada M, Okudaira Y, Matsui Y & Shimizu Y 1983 Immunosuppressive acidic protein in patients with ovarian cancer. Cancer 52 2081-2085.
86. Scambia G, Testa U, Benedetti P, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C & Mancuso S 1994 Interleukin 6 serum levels in patients with gynecological tumors. International Journal of Cancer 57 318-323.
87. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C & Mancuso S 1995 Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. British Journal of Cancer 71 354-356.
88. Scambia G, Foti E, Ferrandina G, Leone FP, Gadducci A, Benedetti-Panici P & Mancuso S 1996 Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer. American Journal of Obstetrics and Gynecology 175 1606-1610.
89. Schaafsma MR, Fibbe WE, Van Damme J, Duinkerken N, Ralph P, Kaushansky K, Altrock BW, Willemze R & Falkenburg JH 1989 Interleukin-6 is not involved in the interleukin-1-induced production of colony-stimulating factors by human bone marrow stromal cells and fibroblasts. Blood 74 2619-2623.
90. Schildkraut JM, Bastos E & Berchuck A 1997 Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer [see comments]. Journal of the National Cancer Institute 89 932-938.
91. Scholl SM, Bascou CH, Mosseri V, Olivares R, Magdelenat H, Dorval T, Palangie T, Validire P, Pouillart P & Stanley ER 1994 Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. British Journal of Cancer 69 342-346.
92. Schondorf T, Engel H, Lindemann C, Kolhagen H, von Rucker AA & Mallmann P 1997 Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours. Cancer Immunology and Immunotherapy 44 88-96.
93. Schwartz RH 1996 Models of T cell anergy: is there a common molecular mechanism? Journal of Experimental Medicine 184 1-8.
94. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F & Kurzrock R 1997 Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. American Journal of Medicine 102 21-28.
95. Shibata Y, Tamura K & Ishida N 1983 In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of alpha 1-acid protein, in connection with its high level in tumor-bearing mice. Cancer Research 43 2889-2896.
96. 2. Journal of Experimental Medicine 180 2365-2370.
97. Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T & Nagatomo M 1993 Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer [see comments]. Obstetrics and Gynecology 82 946-950.
98. Suzuki M, Ohwada M, Sato I & Nagatomo M 1995 Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies. Oncology 52 128-133.
99. Taga K & Tosato G 1992 IL-10 inhibits human T cell proliferation and IL-2 production. Journal of Immunology 148 1143-1148.
100. Takcuchi M, Kosiewicz MM, Alard P & Streilein JW 1997 On the mechanisms by which transforming growth factor-beta2 alters antigen-presenting abilities of macrophages on T cell activation. European Journal of Immunology 27 1648-1656.
101. Tamura K, Shibata Y, Matsuda Y & Ishida N 1981 Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Research 41 3244-3252.
102. Taub DD, Anver M, Oppenheim JJ, Longo DL & Murphy WJ 1996 T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. Journal of Clinical Investigation 97 1931-1941.
103. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E & Kainz C 1997 Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecologic Oncology 66 27-30.
104. Tepler I, Elias L, Smith JW 2nd, Hussein M, Rosen G, Chang AY, Moore JO, Gordon MS, Kuca B, Beach KJ, Loewy JW, Garnick MB & Kaye JA 1996 A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87 3607-3614.
105. Terranova PF & Rice VM 1997 Review - cytokine involvement in ovarian processes. American Journal of Reproductive Immunology 37 50-63.
106. Vánky F, Nagy N, Hising C, Sjövall K, Larson B & Klein E 1997 Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunology and Immunotherapy 43 317-323.
107. Vinatier D, Dufour P, Tordjeman-Rizzi N, Prolongeau JF, Depret-Moser S & Monnier JC 1995 Immunological aspects of ovarian function: role of the cytokines. European Journal Obstetrics, Gynecology and Reproductive Biology 63 155-168.
108. de Waal Malefyt R, Haanen J, Spits H, Roncarolo M-G, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H & de Vries JE 1991 Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. Journal of Experimental Medicine 174 915-924.
109. Watson JM, Sensintaffar JL, Berek JS & Martinez-Maza O 1990 Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Research 50 6959-6965.
110. Weller M, Constam DB, Malipiero U & Fontana A 1994 Transforming growth factor-β2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. European Journal of Immunology 24 1293-1300.
111. Wrana JL & Attisano L 1996 MAD-related proteins in TGF-beta signalling. Trends in Genetics 12 493-496.
112. Wrana JL, Attisano L, Wiesser R, Ventura F & Massagué J 1994 Mechanism of activation of the TGF-β receptor. Nature 370 341-347.
113. Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D & Bast RC Jr 1991 Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. American Journal of Obstetrics and Gynecology 165 1356-1362.
114. Yamaguchi Y, Miyahara E, Funakoshi M, Takashima I, Kawami H, Sato Y & Toge T 1995 Modulation of CD4 antigen expression on the lymphocyte surface by immunosuppressive acidic protein in cancer patients. Oncology 52 1-6.
115. Yingling JM, Datto MB, Wong C, Frederick JP, Liberati NT & Wang XF 1997 Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Molecular and Cellular Biology 17 7019-7028.
116. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD & Fidler IJ 1998 Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. Journal of the National Cancer Institute 90 447-454.
117. Yoshizawa K, Naruto M & Ida N 1996 Injection time of interleukin-6 determines fatal outcome in experimental endotoxin shock. Journal of Interferon and Cytokine Research 16 995-1000.
118. Young MRI, Wright MA, Matthews JP, Malik I & Prechel M 1996 Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. Journal of Immunology 156 1916-1922.
119. Zachos G & Spandidos DA 1998 Transcriptional regulation of the c-H-ras1 gene by the P53 protein is implicated in the development of human endometrial and ovarian tumours. Oncogene 16 3013-3017.
120. van der Zee AGJ, de Cuyper EMJ, Limburg PC, de Bruijn HWA, Hollema H, Bijzet J, Krans M & de Vries GE 1995 Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer 75 1004-1009.
121. Zhao J & Buick RN 1995 Regulation of transforming growth factor β receptors in H-ras oncogene-transformed rat intestinal epithelial cells. Cancer Research 55 6181-6188.
122. Zhao Y, Rong H & Chegini N 1995 Expression and selective cellular localization of granulocyte-macrophage colony-stimulating factor (GM-CSF) and GM-CSF alpha and beta receptor messenger ribonucleic acid and protein in human ovarian tissue. Biology of Reproduction 53 923-930.